Hiroo Matsuo

Dr. Hiroo Matsuo

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PDF file
RSRyuichi Minoda Sada
Ryuichi Minoda Sada
HMHiroo Matsuo
Hiroo Matsuo
DMDaisuke Motooka
Daisuke Motooka
SKSatoshi Kutsuna
Satoshi Kutsuna
SHShigeto Hamaguchi
Shigeto Hamaguchi
AUAkiko Ueda
Akiko Ueda
Clostridium butyricum, a probiotic commonly prescribed in Asia, most notably as MIYA-BM (Miyarisan Pharmaceutical Co., Ltd.; https://www.miyarisan.com ), occasionally leads to bacteremia. The prevalence and characteristics of C. butyricum bacteremia and its bacteriologic and genetic underpinnings remain unknown. We retrospectively investigated patients admitted to Osaka University Hospital during September 2011–February 2023. Whole-genome sequencing revealed 5 (0.08%) cases of C. butyricum bacteremia among 6,576 case-patients who had blood cultures positive for any bacteria. Four patients consumed MIYA-BM, and 1 patient consumed a different C. butyricum-containing probiotic. Most patients had compromised immune systems, and common symptoms included fever and abdominal distress. One patient died of nonocclusive mesenteric ischemia. Sequencing results confirmed that all identified C. butyricum bacteremia strains were probiotic derivatives. Our findings underscore the risk for bacteremia resulting from probiotic use, especially in hospitalized patients, necessitating judicious prescription practices.

12 November 2024 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KKKeiji Konishi
Keiji Konishi
HMHiroo Matsuo
Hiroo Matsuo
MSMichinori Shirano
Michinori Shirano

15 September 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
HMHiroo Matsuo
Hiroo Matsuo
KFKensuke Fujiwara
Kensuke Fujiwara
MNMakoto Niki
Makoto Niki
SKSatoshi Kutsuna
Satoshi Kutsuna
Recent environmental changes and advances in modern medicine—particularly the increasing use of immunosuppressive therapies and organ transplantation—have led to a growing number of infections caused by fungi that were previously not recognized as human pathogens. We report a case of pulmonary infection caused by Trametes elegans and Peniophora incarnata in a 27-year-old man with advanced acquired immunodeficiency syndrome who presented with multiple bilateral pulmonary nodules. Both fungi, which are rare environmental homobasidiomycetes, were identified using molecular methods. Thermal tolerance was demonstrated by T. elegans, supporting its ability to proliferate in human lungs, while P. incarnata showed limited growth at 35 °C. Initial treatment with liposomal amphotericin B was ineffective; however, the patient's condition improved following a switch to voriconazole. Climate change may increase the incidence of such opportunistic infections in individuals with compromised immunity.

21 August 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
HMHiroo Matsuo
Hiroo Matsuo
KYKairi Yonekura
Kairi Yonekura
SKSatoshi Kutsuna
Satoshi Kutsuna
Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare neuroimmunological disorder with diverse etiologies, including infection-associated triggers such as human immunodeficiency virus (HIV) infection. Herein, we report a case of HIV-associated OMAS in an antiretroviral therapy (ART)-naïve patient who presented with cerebrospinal fluid (CSF)/plasma HIV-1 RNA discordance. A 16-year-old female was diagnosed with HIV following the onset of OMAS. The CSF HIV-1 RNA level was higher than that in the plasma. After ART initiation, both the CSF HIV viral load and OMAS symptoms improved simultaneously. This case demonstrates that CSF/plasma HIV-1 RNA discordance can occur in ART-naïve patients with HIV-associated OMAS. Moreover, our findings suggest that, in such cases, viral suppression through ART alone may be sufficient to achieve clinical resolution without the need for adjunctive immunosuppressive therapy.

8 December 2023 in Life
Verified
Journal Article
Open access
PDF file
KKKeiji Konishi
Keiji Konishi
DODaisuke Onozuka
Daisuke Onozuka
STSatoko Takatera
Satoko Takatera
HMHiroo Matsuo
Hiroo Matsuo
HYHisao Yoshida
Hisao Yoshida
SKSatoshi Kutsuna
Satoshi Kutsuna
Mouthwashes containing cetylpyridinium chloride (CPC) or on-demand aqueous chlorine dioxide (ACD) have potential to reduce the salivary severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) load in individuals with SARS-CoV-2 infection. This study will evaluate the effect of CPC and on-demand ACD mouthwashes on salivary SARS-CoV-2 levels in individuals with acute asymptomatic or mild SARS-CoV-2 infection (COVID-19) staying in a residential recuperation facility in Osaka, Japan. This randomized, open-label clinical trial will include three equal-sized groups (CPC mouthwash, on-demand ACD mouthwash, and placebo), with 30 participants per group. A stratified replacement block method will be used to ensure balanced allocation based on symptom presence and days since symptom onset. Participants will use mouthwash at set times for 7 days or until the end of recuperation. Saliva samples will be collected at multiple time points and tested for SARS-CoV-2 using quantitative reverse transcription polymerase chain reaction. The primary outcome will be changes in salivary SARS-CoV-2 viral load 2 h after the first mouthwash use compared with the pre-mouthwash level. Secondary outcomes will include changes in salivary viral load and clinical parameters at different time points. This study was registered with the Japan Registry of Clinical Trials on 18 October 2022 (jRCTs051220107).

3 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
HHHisayo Horiuchi
Hisayo Horiuchi
YKYoshiki Kusama
Yoshiki Kusama
HMHiroo Matsuo
Hiroo Matsuo
SKSatoshi Kutsuna
Satoshi Kutsuna
Background/Objectives: COVID-19 vaccination rate among children in Japan is low. This study aimed to address the knowledge, attitudes, and practices (KAP) regarding parental COVID-19 vaccine acceptance and hesitancy among parents with infants. Methods: We conducted a paper-based, household. Survey asked COVID-19 vaccination status, knowledge and attitudes among households with a vaccinated child, knowledge and attitudes among households with a non-vaccinated child, and intention to vaccinate among households with a non-vaccinated child. To analyze the factors associated with parental behavior, univariate and multivariate analyses were performed. Results: Response sheets were mailed to 1,060 households, and 960 children; and 665 respondents agreed to participate in the study. Only 3.8% of the children received the COVID-19 vaccine. In the multivariate analysis, parents who received three or more doses of the COVID-19 vaccine was associated with the child’s vaccination status (adjusted OR 8.24, p < 0.01). Among respondents with a vaccinated child, 28.0% and 28.0% answered that vaccines can prevent long-term effects and complications and that COVID-19 is a serious infection, respectively. Sixteen percent said that social media platforms influenced their decision to vaccinate. Among the respondents with a non-vaccinated child, 38.9% answered that they had insufficient data on vaccine safety, while 26.7% answered that television and online news influenced their decision. Only 1.2% answered that they were planning to get the COVID-19 vaccine in the future. Conclusions: This KAP survey found a low rate of vaccination against COVID-19 among infants. These findings will contribute to the formulation of future public health practices.